1999
DOI: 10.1006/jmbi.1999.3156
|View full text |Cite
|
Sign up to set email alerts
|

Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
129
0

Year Published

2000
2000
2015
2015

Publication Types

Select...
5
4

Relationship

1
8

Authors

Journals

citations
Cited by 183 publications
(130 citation statements)
references
References 62 publications
1
129
0
Order By: Relevance
“…23 Its derivatives include, but are not limited to, dsDb (interchain disulfide bond between V L and V H of the same antibody), 24 DART (dual-affinity re-targeting, interchain disulfide bond between 2 V L ), 25 scDb (single chain Diabody), 26 and tandAbs (Diabody dimer via flexible linkers in between). 27 The other is the BiTE Ò (bispecific T-cell engager), which is composed of 2 scFvs connected in tandem by an adjustable linker. 28 Because of their unique structural features, the more compact Diabody is often employed as a diagnostic tool or drug delivery vehicle, 29 while BiTEs are generally developed as anti-cancer therapeutics to co-localize T cells and tumor cells to form immunologic synapses and therefore trigger tumor cell cytotoxicity.…”
Section: Introductionmentioning
confidence: 99%
“…23 Its derivatives include, but are not limited to, dsDb (interchain disulfide bond between V L and V H of the same antibody), 24 DART (dual-affinity re-targeting, interchain disulfide bond between 2 V L ), 25 scDb (single chain Diabody), 26 and tandAbs (Diabody dimer via flexible linkers in between). 27 The other is the BiTE Ò (bispecific T-cell engager), which is composed of 2 scFvs connected in tandem by an adjustable linker. 28 Because of their unique structural features, the more compact Diabody is often employed as a diagnostic tool or drug delivery vehicle, 29 while BiTEs are generally developed as anti-cancer therapeutics to co-localize T cells and tumor cells to form immunologic synapses and therefore trigger tumor cell cytotoxicity.…”
Section: Introductionmentioning
confidence: 99%
“…To overcome some of the remaining weaknesses of this format, such as an unfavourable plasma retention, the format has been further improved by expanding it to tandem diabodies (Kipriyanov et al, 1999) and singlechain triplebodies (sctbs; Kellner et al, 2008). The incorporation of a second scFv-binding site for tumour-antigens in these extended formats has led to increased avidity for the tumour cell, increased anti-tumour activity in antibody-dependent cellular cytotoxicity (ADCC) reactions, and improved plasma retention in vivo (Kellner et al, 2008).…”
mentioning
confidence: 99%
“…Single chain diabody-Fc fusion Kipriyanov et al have developed a "single chain" diabody (scDb) by fusing both "cross-over" scFv of a bispecific diabody with a flexible linker [47] . This construct is fused to an Fc fragment (or just a CH3 domain) to create a tetravalent bispecific IgG-like molecule ( Figure 2).…”
Section: Recombinant Approaches To Igg or Igg-like Bsabmentioning
confidence: 99%